Cantargia AB CANTA

LUND, SE / ACCESS Newswire / September 30, 2026 / AB (publ) (STO:CANTA) today announced the presentation of a poster on nadunolimab in combination with RAS inhibition in pancreatic ductal adenocarcinoma (PDAC) at the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development. The preclinical data were generated in a research study at Fred Hutch Cancer Center.

LUND, SE / ACCESS Newswire / August 28, 2026 / AB (publ) (Nasdaq Stockholm:CANTA) today announced that management will participate in the following investor conferences during September 2026. Wainwright - 28th Annual Global Investment Conference 2026, New York * Company Presentation by Hilde Steineger, CEO * Investor meetings * September 14 at 10.

Company reports complete remission in all evaluable high-risk MDS patients and secures funding to extend runway into mid-2028.

LUND, SE / ACCESS Newswire / August 19, 2026 / Cantargia AB (publ) (STO:CANTA) today published its interim report for the second quarter and first six months of 2026. "Over the next nine to twelve months, we will lay the groundwork for a broader set ...

LUND, SE / ACCESS Newswire / August 4, 2026 / Cantargia AB (publ), "Cantargia" (STO:CANTA) will publish its interim report for January - June 2026 on Wednesday, August 19, 2026, at 07:00 a.m. CEST. Interested investors, analysts, and media are invited ...

LUND, SE / ACCESS Newswire / July 31, 2026 /Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia has changed due to the recently completed rights issue (for further information, ...

LUND, SE / ACCESS Newswire / June 26, 2026 / Cantargia AB (publ) (STO:CANTA) today announced the publication of preclinical and clinical findings from the nadunolimab trial CANFOUR in the scientific journal JCI Insight. The results underscore the ...

LUND, SE / ACCESS Newswire / June 10, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current or previous smokers with multifocal high-risk ...

LUND, SE / ACCESS Newswire / May 28, 2026 / Cantargia (STO:CANTA) - With reference to the Company's press release on May 28, 2026, regarding the decision to conduct a rights issue in combination with a loan, Cantargia AB (Publ) ("Cantargia" or the ...

LUND, SE / ACCESS Newswire / May 21, 2026 / Cantargia (STO:CANTA) - The Annual General Meeting of Cantargia AB (publ) on May 21, 2026 resolved in accordance with the following: To adopt the income statement and balance sheet as well as to allocate ...

Cantargia AB (FRA:7V3) refines its focus on promising therapies while navigating financial hurdles and evolving treatment paradigms.

LUND, SE / ACCESS Newswire / May 19, 2026 / Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for the first quarter of 2026. "The first quarter of 2026 reflects both strong execution and important strategic progress for ...

LUND, SE / ACCESS Newswire / May 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for Q1 2026 on Tuesday, May 19, 2026, at 07:00 a.m. CEST. In conjunction to the report, investors, analysts, and media ...

LUND, SE / ACCESS Newswire / April 27, 2026 / Cantargia AB (Nasdaq Stockholm:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced early results from the ongoing Phase 1b/2a clinical ...

LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (Nasdaq Stockholm:CANTA) today reported that the rationale and study design of the phase 1b/2 clinical trial investigating nadunolimab in combination with immune-checkpoint ...